EUVIMEDEUVIMED entdecken
Open Access

Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein

Hongliang Jin iD, Lin Cheng, Yani Gong, Yuanmei Zhu, Huihui Chong, Zheng Zhang, Yuxian He iD

Journal of Virology · 2023

DOI: 10.1128/jvi.00192-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2023. Verfasst von Hongliang Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical Colle…. Hauptthemen laut MEDLINE: COVID-19, Severe acute respiratory syndrome-related coronavirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CAMS Innovation Fund for Medical Sciences, China Postdoctoral Science Foundation, Shenzhen Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of highly effective antivirals that are robust to viral evolution is a practical strategy for combating the continuously evolved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Inspired by viral multistep entry process, we here focus on developing a bispecific SARS-CoV-2 entry inhibitor, which acts on the cell receptor angiotensin converting enzyme 2 (ACE2) and viral S2 fusion protein. First, we identified a panel of diverse spike (S) receptor-binding domains (RBDs) and found that the RBD derived from Guangdong pangolin coronavirus (PCoV-GD) possessed the most potent antiviral potency. Next, we created a bispecific inhibitor termed RBD-IPB01 by genetically linking a peptide fusion inhibitor IPB01 to the C-terminal of PCoV-GD RBD, which exhibited greatly increased antiviral potency via cell membrane ACE2 anchoring. Promisingly, RBD-IPB01 had a uniformly bifunctional inhibition on divergent pseudo- and authentic SARS-CoV-2 variants, including multiple Omicron subvariants. RBD-IPB01 also showed consistently cross-inhibition of other sarbecoviruses, including SARS-CoV, PCoV-GD, and Guangxi pangolin coronavirus (PCoV-GX). RBD-IPB01 displayed low cytotoxicity, high trypsin resistance, and favorable metabolic stability. Combined, our studies have provided a tantalizing insight into the design of broad-spectrum and potent antiviral agent. IMPORTANCE Ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution and spillover potential of a wide variety of sarbecovirus lineages indicate the importance of developing highly effective antivirals with broad capability. By directing host angiotensin converting enzyme 2 receptor and viral S2 fusion protein, we have created a dual-targeted virus entry inhibitor with high antiviral potency and breadth. The inhibitor receptor-binding domain (RBD)-IPB01 with the Guangdong pangolin coronavirus (PCoV-GD) spike RBD and a fusion inhibitor IPB01 displays bifunctional cross-inhibitions on pseudo- and authentic SARS-CoV-2 variants including Omicron, as well as on the sarbecoviruses SARS-CoV, PCoV-GD, and Guangxi pangolin coronavirus. RBD-IPB01 also efficiently inhibits diverse SARS-CoV-2 infection of human Calu-3 cells and blocks viral S-mediated cell-cell fusion with a dual function. Thus, the creation of such a bifunctional inhibitor with pan-sarbecovirus neutralizing capability has not only provided a potential weapon to combat future SARS-CoV-2 variants or yet-to-emerge zoonotic sarbecovirus, but also verified a viable strategy for the designing of antivirals against infection of other enveloped viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Severe acute respiratory syndrome-related coronavirusHumansAnimalsSARS-CoV-2Angiotensin-Converting Enzyme 2PangolinsSpike Glycoprotein, CoronavirusChinaViral Fusion ProteinsAntiviral Agents

Stichwörter der Autor:innen

SARS-CoV-2bifunctional entry inhibitorfusion inhibitorreceptor-binding domain (RBD)sarbecoviruses

Substanzen

Angiotensin-Converting Enzyme 2Spike Glycoprotein, CoronavirusViral Fusion ProteinsAntiviral Agentsspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China.
  • Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology , Sh…

ORCID-Profile: Hongliang Jin, Yuxian He

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • China Postdoctoral Science Foundation
  • Shenzhen Science and Technology Program
  • MOST | National Natural Science Foundation of China

Zitieren

APA

Jin, H., Cheng, L., Gong, Y., Zhu, Y., Chong, H., Zhang, Z., & He, Y. (2023). Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Journal of Virology. https://doi.org/10.1128/jvi.00192-23

Vancouver

Jin H, Cheng L, Gong Y, Zhu Y, Chong H, Zhang Z, et al. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Journal of Virology. 2023. doi:10.1128/jvi.00192-23

BibTeX
@article{Jin2023,
  author = {Jin, Hongliang and Cheng, Lin and Gong, Yani and Zhu, Yuanmei and Chong, Huihui and Zhang, Zheng and He, Yuxian},
  title = {Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein},
  journal = {Journal of Virology},
  year = {2023},
  doi = {10.1128/jvi.00192-23}
}
Kostenlos starten →